Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration

Stephen J. Freedland | Rickard Sandin | Janvi Sah | Birol Emir | Qiao Mu | Anna Ratiu | Agnes Hong | Lucile Serfass | Scott T. Tagawa

Abstract

Background: Limited real-world data exist on treatment patterns and outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC).

Methods: A retrospective cohort study was conducted, using the Veterans Health Administration claims database (April 2013–March 2018). Among 369,734 prostate cancer patients, we selected all men who developed metastases within 90 days before or after medical/surgical castration and who received androgen deprivation therapy (ADT). Patients were categorized into four cohorts: ADT-only (± <90-day nonsteroidal anti-androgen [NSAA] use), ADT + NSAA, ADT + docetaxel, and ADT + abiraterone. Main outcomes were treatment patterns, time-to-progression to metastatic castration-resistant disease, and overall survival. Multivariable analysis and sensitivity analysis were conducted.

Results: Of 1395 patients, 874 (63%) received ADT-only, 338 (24%) received ADT + NSAA, 108 (8%) received ADT + docetaxel, and 75 (5%) received ADT + abiraterone. Proportions on ADT-only and ADT + NSAA declined (from 66% to 60% and from 31% to 17%, respectively) over the study period, while proportions prescribed ADT + docetaxel or abiraterone increased from 3% to 9% and from 1% to 15%, respectively. Patients treated with ADT + NSAA had similar risks of castration-resistant disease (hazard ratio [HR] 1.05; 95% confidence interval [CI]: 0.87, 1.26) and overall mortality (HR 1.22; 95% CI: 0.97, 1.54) as ADT-only.

Conclusions: Most patients with mCSPC initiating ADT received ADT-only or ADT + NSAA, despite the emergence of docetaxel and novel hormonal therapies. Even in the most recent period (2017 to early 2018), only 24% of men received intensified therapy with agents known to prolong survival versus ADT-only. These data in real-world clinical practice suggest substantial room for improved outcomes in patients with mCSPC.

KEYWORDS
anti-androgen, LHRH agonist, LHRH antagonist, overall survival, prostate cancer

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
1 | INTRODUCTION

Prostate cancer is the most common cancer diagnosis and the second most common cause of cancer-related mortality in men in the United States, with an estimated 248,530 new cases and 34,130 deaths in 2021. Metastatic castration-sensitive prostate cancer (mCSPC) is prostate cancer that has extended beyond the prostate in the setting of normal serum levels of testosterone, that usually responds to androgen deprivation therapy (ADT).

Current practice guidelines recommend ADT with novel hormonal therapies (NHTs: abiraterone, apalutamide, or enzalutamide) or docetaxel as the initial standard of care for patients with mCSPC. Short-term use of a first-generation nonsteroidal anti-androgen (NSAA [bicalutamide, flutamide, or nilutamide]) is currently recommended for treating temporary testosterone flare commonly seen with many ADT approaches. An alternative approach is to use ADT in conjunction with an NSAA to achieve complete androgen blockade, although current guidelines note that there is likely minimal added benefit of combined androgen blockade.

In recent years, multiple clinical trials have demonstrated that adding chemotherapy or NHTs to ADT leads to significantly prolonged progression-free survival (PFS) and overall survival (OS) in patients with mCSPC. Based on these findings, a combination of ADT and docetaxel, abiraterone, apalutamide, or enzalutamide is recommended for mCSPC.

While data on survival rates are accumulating from clinical trials, limited real-world evidence of clinical benefit exists for patients with mCSPC in the United States. Real-world data can validate and expand on trial outcomes as well as provide information on treatment patterns and uptake of new pharmacotherapies across a broader patient population. The objective of this study was to evaluate patient characteristics, treatment patterns, time-to-progression to metastatic castration-resistant prostate cancer (mCRPC), and OS among men with mCSPC who initiated either ADT-only or ADT with NSAA, docetaxel, or abiraterone acetate, using the US Veterans Health Administration (VHA) database.

2 | METHODS

2.1 | Patient Selection and Study Design

This retrospective cohort study was based on claims data extracted from the VHA database within a 5-year study period (1 April 2013–31 March 2018), which comprised a 4-year identification period (1 April 2014–31 March 2018) and a 12-month pre-index (baseline) period. From a cohort of 369,734 patients with a first claim for prostate cancer during the study period, 1395 had metastases within 90 days before or after medical/surgical castration (the initial ADT date) during the identification period and received ADT-only or ADT with the addition of NSAA, docetaxel, or abiraterone. CSPC was defined as use of ADT for ≥3 months (without a gap of ≥90 days between two claims), and without documented use of NSAA, NHTs, or docetaxel in the 12 months preceding the initial ADT date. Patients who received antineoplastic therapies during the baseline period were excluded, as were patients receiving enzalutamide, given that the study time period pre-dated its approval for mCSPC (complete selection criteria are shown in Figure S1). Prior adjuvant ADT was allowed, that is, if received prior to 12 months before the date of first metastases. Patients with mCSPC who met the selection criteria were categorized into four cohorts:

- **ADT + abiraterone (n = 75):** Patients with claims for abiraterone within 4 months after or within 30 days prior to ADT initiation were classified as ADT + abiraterone.
- **ADT + docetaxel (n = 108):** Patients with claims for docetaxel within 4 months after or within 30 days prior to ADT initiation were classified as ADT + docetaxel.
- **ADT + NSAA (n = 338):** Patients prescribed NSAA for ≥3 months after the initial ADT date were classified as ADT + NSAA. Patients treated with NSAA for <3 months (likely for testosterone flare) were classified as ADT-only.
- **ADT-only (n = 874):** Patients with mCSPC who received ADT-only (i.e., did not receive the treatments
The index date was defined as the start of ADT, abiraterone, docetaxel, or NSAA, whichever occurred first.

2.2 | Study measures

2.2.1 | Baseline patient characteristics

Baseline demographics (age, race, and index year) and clinical variables (comorbidity index score, which did not include cancer, and individual comorbidities) were measured during the 12 months prior to the index date. Time from diagnosis of metastasis to index date plus site of metastasis (lymph node, respiratory and digestive, other [including bone], and unspecified sites) were measured within ±90 days of the index date. Prognostic factors, including serum prostate-specific antigen (PSA), hemoglobin, and alkaline phosphatase concentrations were measured within ±6 months prior to the index date to include the maximum number of patients with the selected prognostic variables. When multiple values were available, we used the values closest to, but before, the index date.

2.2.2 | Survival outcomes

Patients were followed from the index date to the earliest of death or the end of the study. OS and progression to mCRPC were evaluated during follow-up. Progression to mCRPC was defined as:

- Change in index therapy or evidence of cabazitaxel, mitoxantrone, abiraterone, docetaxel, enzalutamide, radium-223, or sipuleucel-T after 4 months from the index date until the end of follow-up; or
- An increase in PSA concentration of ≥25% and 2 ng/ml from the nadir value (lowest PSA value ≥14 days from the index date) evaluated from the index date until discontinuation of ADT (defined as a gap >90 days between 2 ADT claims); or
- Among patients who re-initiated ADT, if their first PSA value after re-initiation was ≥ the last PSA value before re-initiation of ADT.

Time-to-event endpoints were determined from the index date. Given low statistical power, we did not evaluate time to mCRPC and OS in ADT + abiraterone- or ADT + docetaxel-treated patients.

2.2.3 | Treatment patterns

Patients who progressed to mCRPC were evaluated for subsequent lines of treatment. Among patients who progressed to mCRPC, evidence of change in therapy (cabazitaxel, mitoxantrone, abiraterone acetate, docetaxel, enzalutamide, radium-223, or sipuleucel-T) observed on or after the mCRPC date was considered the beginning of second-line (2L) therapy. Additionally, if patients in the ADT + abiraterone group or ADT + docetaxel group reinitiated abiraterone or docetaxel, respectively (after a lapse of >90 days) during follow-up, it was considered 2L treatment. Change in therapy after 2L treatment was defined as third-line (3L) treatment, and change in therapy after the 3L treatment was defined as fourth-line treatment.

2.3 | Statistical analysis

Descriptive statistics were generated for all study variables. This included means and standard deviations for normally distributed continuous variables, and medians and interquartile ranges for skewed continuous variables. Treatment patterns and distribution across lines of therapy and sequencing were analyzed with Sankey flow diagrams connecting a series of events over time to visualize treatment along the mCSPC patient journey. The Kaplan–Meier analysis was used to estimate the unadjusted survival curves for mCRPC and OS.

Multivariable analysis with inverse probability treatment weighting (IPTW) was applied to the main analysis to balance patient characteristics and potential confounders when comparing outcomes among ADT + NSAA and ADT-only cohorts while retaining all eligible subjects. Lasso penalized regression was used to select covariates with the most explanatory value for the survival outcomes. Covariates (listed in Table 1) were used to define the probability of a patient receiving a certain treatment. Age and race were exact matched in IPTW. Post-IPTW, Schoenfeld residuals plots indicated that body mass index (BMI) produced a nonlinear effect on the models, and hence BMI and BMI^2 (quadratic term) were included in the survival models to offset non-proportionality assumption (model fit). Additionally, site of metastatic diagnosis, time from metastatic diagnosis to index date, and log PSA concentration were included in the model based on clinical rationale. Progression to mCRPC and OS were evaluated using a Cox proportional hazard model while adjusting for the above covariates.
|                                | ADT-only (reference) | ADT + NSAA | STD\(^a\) | ADT + abiraterone | STD\(^a\) | ADT + docetaxel | STD\(^a\) |
|--------------------------------|----------------------|------------|-----------|-------------------|-----------|----------------|-----------|
| Sample size (N = 1395); n (%)  | 874 (63)             | 338 (24)   | 75 (5)    | 108 (8)           |           |                |           |
| Age (y), n (%)                 |                      |            |           |                   |           |                |           |
| Mean (SD)                      | 73.4 (9.8)           | 74.5 (9.7) | 11.09     | 75.3 (8.6)        | 20.50     | 65.8 (7.1)     | 89.18     |
| Median (Q25–Q75)               | 72 (67–82)           | 74 (67–82) | 73 (70–83)| 67 (61–71)        |           |                |           |
| ≤59                            | 60 (7)               | 17 (5)     | 7.76      | 2 (3)             | 19.76     | 20 (19)        | 35.43     |
| 60–69                          | 297 (34)             | 110 (33)   | 3.05      | 15 (20)           | 31.79     | 55 (51)        | 34.70     |
| 70–79                          | 251 (29)             | 88 (26)    | 6.01      | 33 (44)           | 32.05     | 30 (28)        | 2.08      |
| ≥80                            | 266 (30)             | 123 (36)   | 12.64     | 25 (33)           | 6.20      | 3 (3)          | 79.97     |
| Race, n (%)                    |                      |            |           |                   |           |                |           |
| White                          | 555 (64)             | 238 (70)   | 14.72     | 49 (65)           | 3.81      | 78 (72)        | 18.71     |
| Black                          | 247 (28)             | 77 (23)    | 12.58     | 18 (24)           | 9.68      | 23 (21)        | 16.15     |
| Other/unknown                  | 72 (8)               | 23 (7)     | 5.43      | 8 (11)            | 8.28      | 7 (6)          | 6.71      |
| NCI comorbidity index score    |                      |            |           |                   |           |                |           |
| Mean (SD)                      | 1.5 (1.7)            | 1.4 (1.7)  | 6.00      | 1.4 (1.6)         | 7.4       | 1.1 (1.5)      | 30.0      |
| Median (Q25–Q75)               | 1 (0–2)              | 1 (0–2)    | 1 (0–2)   | 1 (0–1)           |           |                |           |
| Baseline comorbidities, n (%)  |                      |            |           |                   |           |                |           |
| Acute coronary syndrome        | 61 (7)               | 17 (5)     | 8.21      | 3 (4)             | 13.07     | 5 (5)          | 10.04     |
| Angina pectoris                | 18 (2)               | 12 (4)     | 9.03      | 3 (4)             | 11.29     | 1 (1)          | 9.34      |
| Arrhythmia                     | 63 (7)               | 33 (10)    | 9.17      | 2 (3)             | 21.03     | 3 (3)          | 20.41     |
| Chronic obstructive pulmonary disease | 135 (15) | 60 (18)   | 6.19      | 6 (8)             | 23.24     | 14 (13)        | 7.10      |
| Congestive heart failure       | 71 (8)               | 34 (10)    | 6.73      | 5 (7)             | 5.55      | 2 (2)          | 29.07     |
| Diabetes                       | 298 (34)             | 94 (28)    | 13.61     | 26 (35)           | 1.20      | 31 (29)        | 11.61     |
| Hyperlipidemia                 | 470 (54)             | 188 (56)   | 3.70      | 36 (48)           | 11.53     | 54 (50)        | 7.54      |
| Hypertension                   | 645 (74)             | 245 (72)   | 2.96      | 49 (65)           | 18.40     | 66 (61)        | 27.25     |
| Myocardial infarction          | 26 (3)               | 16 (5)     | 9.14      | 4 (5)             | 11.79     | 1 (1)          | 14.83     |
| Stroke                         | 50 (6)               | 27 (8)     | 8.97      | 3 (4)             | 7.98      | 6 (6)          | 0.71      |
| Urinary tract infection        | 101 (12)             | 30 (9)     | 8.85      | 9 (12)            | 1.37      | 10 (9)         | 7.51      |
| Obesity                        | 297 (34)             | 96 (28)    | 12.05     | 21 (28)           | 12.92     | 41 (38)        | 8.28      |
| Prognostic variables\(^b\)    |                      |            |           |                   |           |                |           |
| PSA value (ng/mL)              |                      |            |           |                   |           |                |           |
| Mean (SD)                      | 256.5 (696.1)        | 303.1 (773.9) | 6.33 | 238.3 (524.3) | 2.96 | 338.1 (866.8) | 10.38 |
| Median (Q25–Q75)               | 31.5 (8.5–126.2)     | 51.3 (13.0–207.2) | 36.4 (11.1–96.1) | 11.79 | 1 (1) | 14.83 |
| Hemoglobin (g/dL)              |                      |            |           |                   |           |                |           |
| Mean (SD)                      | 12.8 (2.1)           | 13.1 (2.0) | 13.57     | 12.1 (2.1)        | 31.58     | 13.4 (2.0)     | 29.37     |
| Median (Q25–Q75)               | 13.0 (11.6–14.2)     | 13.2 (12.1–14.4) | 12.4 (10.6–13.6) | 13.7 (12.3–14.7) |           |                |           |

(Continues)
2.3.1 Sensitivity analysis

To confirm the robustness of the multivariable analysis, 1:2 propensity score matching (PSM) was used as sensitivity analysis. The same covariates as in the main analysis were adopted to define the propensity scores for the patients with mCSPC. Each patient in the ADT + NSAA cohort was matched to two patients in the ADT-only cohort with the closest propensity score. The “nearest neighbor” method without replacement and with a caliper of 0.01 was used to select the matched samples. The balance of covariates between treatment groups was determined using the absolute standardized difference of the mean ≤0.10.

3 RESULTS

Based on the predefined selection criteria, a total of 1395 cases of mCSPC were identified in the VHA database.
including 874 (63%) ADT-only, 338 (24%) ADT + NSAA, 75 (5%) ADT + abiraterone, and 108 (8%) ADT + docetaxel patients (Table 1). Of the patients who had ADT + NSAA, 98% received bicalutamide.

Compared with the ADT-only cohort, ADT + docetaxel patients were younger and had fewer comorbidities, but had greater disease burden in terms of higher PSA and metastases (respiratory and digestive, and other sites including bone), while ADT + abiraterone patients were older, generally had fewer cardiovascular comorbidities, and had higher disease burden in terms of PSA and metastases (other sites including bone); there was also a higher proportion of patients with metastatic lymph node involvement in this group. Patients on ADT + NSAA had similar comorbidity to the ADT-only cohort but were older, with higher disease burden in terms of higher PSA levels and more metastatic sites. Among men with visceral metastases, the majority received ADT alone (54%). ADT + NSAA and ADT + docetaxel patients were less likely to be Black compared to ADT-only patients (Table 1). Descriptive statistics (and unadjusted for baseline characteristics) on treatment by race are shown in Table S1.

From Q2 2014 to Q1 2018, the number of patients receiving ADT-only (66%–60%) and ADT + NSAA (31%–17%) declined, whereas the number of patients prescribed ADT + docetaxel (3%–9%) and ADT + abiraterone (1%–15%) increased (Figure 1). In the most recent period of 2017–Q1 2018, 24% of patients received either docetaxel or abiraterone along with ADT.

### 3.1 Survival outcomes

#### 3.1.1 Unadjusted analysis

The median follow-up was 49.3 months for patients treated with ADT-only, 53.6 months for ADT + NSAA, 19.1 months for ADT + abiraterone, and 45.3 months for ADT + docetaxel. Compared with the ADT-only cohort, with a median time to mCRPC of 24.1 months, unadjusted time to mCRPC was similar for ADT + NSAA (hazard ratio [HR]: 1.12 [95% confidence interval (CI): 0.94, 1.35]; time to mCRPC: 19.6 months; Figure 2A). Compared with the ADT-only cohort, unadjusted OS was lower for the ADT + NSAA cohort (HR: 1.29 [95% CI: 1.03, 1.61]; Figure 2A).

### 3.2 Multivariable adjusted analysis

Multivariable analysis was restricted to a comparison of ADT + NSAA with ADT-only. Table S2 lists the post-IPTW and post-PSM baseline demographic and clinical characteristics. After applying IPTW, all patient characteristics were balanced; median follow-up was 52.2 months for ADT-only and 50.1 months for ADT + NSAA. Forty-seven percent of patients treated with ADT + NSAA progressed to mCRPC compared with 46% of ADT-only patients. Patients treated with ADT + NSAA exhibited similar risk of progression to mCRPC (HR: 1.05 [95% CI: 0.87, 1.26]), with a median time to mCRPC of 21.4 versus 22.5 months compared to ADT-only. During the entire follow-up period, 32% of ADT + NSAA patients died compared with 27% of the ADT-only cohort. Patients treated with ADT + NSAA had a similar risk of death (HR: 1.22 [95% CI: 0.97, 1.54]) compared to ADT-only, with median OS not reached in either cohort (Figure 2B).

### 3.3 Sensitivity analysis

Following PSM, 370 ADT-only and 185 ADT + NSAA pairs were matched. Results of the PSM sensitivity analysis for progression to mCRPC and OS were consistent with those of the IPTW analysis, confirming no difference in time to mCRPC (HR: 1.03 [95% CI: 0.81, 1.33]) and risk of death (HR: 1.33 [95% CI: 0.96, 1.85]) between ADT + NSAA and ADT-only (Figure 2C).

### 3.4 Treatment patterns

Of the 1395 patients, 639 (46%) progressed to mCRPC during the study period. NHT was the most commonly prescribed 2L (abiraterone: 35%; enzalutamide: 22%) and 3L (abiraterone: 13%, enzalutamide: 20%) treatment. A total of 229 (36%) patients who progressed did not receive any 2L treatment. Of these 229 patients, 80 (35%) died while 149 (65%) survived at a median follow-up of 8.1 months after the date of mCRPC. Few patients were prescribed radium-223, sipuleucel-T, or cabazitaxel after progressing to mCRPC (Figure 3).

### 4 DISCUSSION

The landscape of treatment options and recommendations for patients with mCSPC has shifted significantly in recent years, beginning with the survival benefit observed with early administration of docetaxel followed by several NHTs. However, clinical trial data and guidelines do not always reflect real-world treatment patterns. This retrospective, observational study in the VHA setting demonstrated that management of the mCSPC population (from April 2014 to March 2018) was dominated by ADT-only (63%) and ADT + NSAA (24%). A small portion of men
FIGURE 2  (A) Unadjusted time to mCRPC and OS among patients with mCSPC treated with ADT + NSAA versus ADT-only; (B) post-IPTW adjusted time to mCRPC and OS among patients with mCSPC treated with ADT + NSAA versus ADT-only; and (C) sensitivity analysis – post-PSM adjusted time to mCRPC and OS among patients with mCSPC treated with ADT + NSAA versus ADT-only
with more advanced disease received ADT + docetaxel (8%) or ADT + abiraterone (5%). Patients prescribed ADT + docetaxel were, on average, younger. While the use of abiraterone and docetaxel increased over time, it nevertheless remained low by the conclusion of the study period (ADT + docetaxel: 3%–9%; ADT + abiraterone: 1%–15%). For context, data disclosure dates for ADT + docetaxel and ADT + abiraterone were mid-2014 and mid-2017, respectively. Upon progression to mCRPC, the most commonly prescribed pharmacotherapies were abiraterone and enzalutamide. On multivariable analysis, no significant differences were detected between ADT + NSAA in time to mCRPC and OS compared with patients prescribed ADT-only.

Only a few real-world outcomes studies have evaluated treatment patterns and survival outcomes in a large cohort of patients with mCSPC. In line with our study, preliminary results from Ke et al., using a similar study period (2015–2018), indicated that the most common 1L therapy for mCSPC was ADT-only (47%), followed by ADT + docetaxel (8%), ADT + abiraterone (7%), and ADT + NSAA (5%), and that the use of newer therapies had increased yet remained comparatively low. Flaig et al. found that approximately half of the patients enrolled in a US claims database between 2000 and 2013 received ADT-only, although the study period predated widespread use of docetaxel and NHTs. In both studies, >30% of patients did not receive any pharmacotherapy for mCSPC. Excluding non-treated patients in the two studies, the proportion of patients prescribed ADT-only (69% and 74%, respectively) is similar to that of our study (66%).

Of note, Black patients were more likely to receive ADT-only, even though the VHA is an equal access system. While data on treatment by race were not adjusted for potential differences in baseline characteristics, these descriptive data do indicate less treatment intensification among Black patients and therefore disparity by race (Table S1). This is consistent with other studies showing lower rates of treatment intensification among Black patients, for example, a Medicare analysis (2004–2014) of patients with stage IV prostate cancer.4 However, more data over a longer time period with formal adjustment for key covariates are needed.

A substantial proportion (24%) of patients in our study received ADT + NSAA beyond the recommended duration for the treatment of testosterone flare. When correcting for available baseline characteristics, our study found no difference compared to ADT-only in time to mCRPC or death, though unobserved differences in patient characteristics could have impacted results. Our study further supports the mixed opinion of the benefit of long-term anti-androgen therapy. A meta-analysis reported that addition of an anti-androgen (including cyprioterone acetate) was associated with only a 2% improvement in 5-year survival. An alternative interpretation of our data is that adoption of highly effective NHTs in the mCRPC setting in recent years may have contributed to the lack of survival difference with ADT + NSAA versus ADT alone.

Due to the low number of patients in the ADT + abiraterone and ADT + docetaxel cohorts, we were unable to evaluate the time to mCRPC and OS compared to ADT-only by appropriately adjusting for patient characteristics. ADT + abiraterone and ADT + docetaxel were prescribed
to patients with greater disease severity, suggesting that more intensive therapy is reserved for patients with more aggressive disease. However, between 2017 and 2018, even among those with visceral metastases, >40% received ADT alone. In the CHAARTED, STAMPEDE, and LATITUDE studies, adding docetaxel or abiraterone to ADT demonstrated consistent and large OS gains.\textsuperscript{5–11}

In addition, IPTW-adjusted median time to mCRPC was \(\sim\)22 months and 3-year OS was around 60% with ADT-only and ADT + NSAA in our study. This is similar to the median PFS (range: 14.8–22.1 months) and 3-year OS (range: 49%–61%) for the placebo + ADT arms of ARCHES (OS data not yet available), LATITUDE, STAMPEDE, and TITAN, as well as to the corresponding values for the ADT + NSAA arm (\(\sim\)24 months and 72%) in ENZAMET, but inferior to outcomes in the intensified treatment arms (NHT or docetaxel plus ADT) in all these trials.\textsuperscript{7,10,12–15} Since the use of docetaxel and NHTs was low in the current study—despite increasing over time—our study suggests significant room for survival improvement in the mCSPC population.

The majority of the patients in our study who progressed to mCRPC received NHT (57%) as 2L therapy, while 7% received docetaxel. Slightly more than one-third (36%), however, did not receive any 2L treatment after progressing to mCRPC. Our results are in line with George et al. who reported that, among 2559 commercially insured patients initiating mCRPC treatment between 2013 and 2017, the majority received NHTs (65%) as initial treatment, 15% underwent chemotherapy, and 23% did not receive any treatment.\textsuperscript{25} Similarly, in a recent VHA study of mCSPC patients treated with ADT + docetaxel or ADT + abiraterone between 2014 and 2018 who progressed to mCRPC, the vast majority were first treated with an NHT. Among those who received 2L treatment, NHT was most commonly prescribed.\textsuperscript{26}

Limitations of the study include those inherent to claims database analyses, for example, coding errors, inability to guarantee actual treatment administration, and a potential lack of generalizability.\textsuperscript{27} The VHA is however the largest integrated health system in the United States, and any biases due to financial issues are less relevant in this patient population given equal access to care.\textsuperscript{28,29} Importantly, these claims data do not capture information on prognostic factors such as performance status, Gleason score, number of metastases, and high versus low volume disease. In addition, the potential exists for unforeseen confounding of the comparison between ADT + NSAA versus ADT-only.

\section*{5 | CONCLUSIONS}

Practice patterns for mCSPC in the VHA were largely dominated by use of ADT-only treatment and ADT + NSAA, mostly bicalutamide, even in the most recent time period. Patients treated with ADT + NSAA experienced similar time to mCRPC and OS compared with ADT-only, but results should be interpreted with caution as we could not adjust for all prognostic factors. Only a small segment of patients with higher risk disease received ADT + abiraterone or ADT + docetaxel. With the emergence of several newly approved NHTs associated with improved survival in a broad mCSPC population, our study suggests significant room for improved outcomes in this population. The results of this study may help to enhance our understanding of treatment patterns, disease progression, and survival rates of patients with mCSPC beyond the confines of a well-controlled and restricted clinical trial environment.

\section*{ACKNOWLEDGMENTS}

Medical writing and editorial support funded by the sponsors were provided by Matthieu Larchelle, MD, and Donna Vining, DO, of Onyx (a Prime Global agency).

\section*{CONFLICT OF INTEREST}

Stephen J. Freedland—Consulting or advisory role with Astellas Pharma, AstraZeneca, Sanoﬁ, Bayer, Exact Sciences, Janssen, Pfizer, Dendreon, Sanoﬁ, Merck, AstraZeneca, Myovant, and Clovis Oncology. Rickard Sandin, Birol Emir, and Lucile Serfass—Employees of Pfizer Inc., a study sponsor. Janvi Sah, Qiao Mu, and Anna Ratu–Employed by SIMR, Inc., a paid consultant to the sponsors in connection with the development of this manuscript. Agnes Hong–Employee of Astellas Pharma Inc., a study sponsor. Scott T. Tagawa–Consulting or advisory role with Sanoﬁ, Medivation/Astellas, Dendreon, Janssen, Genentech, Bayer, Endocyte, Eisai, Immunomedics, Karyopharm, Abbvie, Tolmar, Seattle Genetics, Amgen, Clovis, QED, Pfizer, AAA/Novartis, Clarity, Genomic Health, POINT Biopharma, Blue Earth Diagnostics, Aikido Pharma, and Gilead Sciences; research funding paid to his institution from Sanoﬁ, Medivation, Astellas, Janssen, Amgen, Progenics, Dendreon, Lilly, Genentech, Newlink, BMS, Inovio, AstraZeneca, Immunomedics, Aveo, Rexahn, Atlab, Boehringer Ingelheim, Millennium, Bayer, Merck, Abbvie, Karyopharm, Endocyte, Clovis, Seattle Genetics, AAA/Novartis, POINT Biopharma, and Gilead Sciences.

\section*{AUTHOR CONTRIBUTIONS}

Stephen J. Freedland–Conceptualization, formal analysis, investigation, methodology, visualization, writing–original draft, writing–review and editing; Rickard Sandin–Conceptualization, formal analysis, funding acquisition, investigation, methodology, project administration, supervision, visualization, writing–original draft, writing–review and editing; Birol
Emir–Conceptualization, formal analysis, investigation, methodology, visualization, writing–original draft, writing–review and editing; Lucile Serfass–Conceptualization, investigation, methodology, visualization, writing–original draft, writing–review and editing; Janvi Sah, Qiao Mu, and Anna Ratiu–Conceptualization, data curation, formal analysis, investigation, methodology, resources, software, validation, visualization, writing–original draft, writing–review and editing; Agnes Hong–Conceptualization, investigation, methodology, visualization, writing–original draft, writing–review and editing; Scott T. Tagawa–Conceptualization, formal analysis, investigation, methodology, visualization, writing–original draft, writing–review and editing.

ETHICAL APPROVAL STATEMENT
The study was exempt from institutional review board or ethics committee approval as it utilized only de-identified claims data.

DATA AVAILABILITY STATEMENT
Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual anonymized participant data. See https://www.pfizer.com/science/clinical-trials/trial-data-and-results for more information.

ORCID
Stephen J. Freedland https://orcid.org/0000-0002-8104-6419

REFERENCES
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7-33.
2. Virgo KS, Rumble RB, de Wit R, et al. Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update. J Clin Oncol. 2021;39(11):1274-1305. 10.1200/JCO.20.03256
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Version 1.2021. https://www.nccn.orgprofessionals/physician_gls/pdf/prostate.pdf. Accessed April 9.
4. Lowrance WT, Breaux RH, Chou R, et al. Advanced prostate cancer: AUA/ASTRO/SUO guideline PART I. J Urol. 2021;205:14-21.
5. Sweeney CJ, Chen Y-H, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737-746.
6. James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1165-1177.
7. Clarke NW, Ali A, Ingleby FC, et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol. 2019;30:1992-2003.
8. James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338-351.
9. James N, Rush H, Clarke N, et al. Abiraterone acetate plus prednisone for hormone-naïve prostate cancer (PCa): long-term results from metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476). Ann Oncol. 2020;31:S509.
10. Fizazi K, Tran NamPhuong, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352-360.
11. Fizazi K, Tran NP, Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20:686-700.
12. Armstrong AJ, Szmulowitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37:2974-2986.
13. Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381:121-131.
14. Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381:13-24.
15. Chi KN, Chowdhury S, Bjartell A, et al. Final analysis results from TITAN: a phase 3 study of apalutamide vs placebo in patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy (Abstract 11). Presentation at Genitourinary Cancers Symposium, ASCO (Feb 11-13, 2021).
16. Ke X, Lafeuille M-H, Romdhani H, et al. Healthcare resource use (HRU) in men with metastatic castration sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT) only or no treatment in the United States (US). J Clin Oncol. 2020;38:e19138.
17. Ke X, Lafeuille M-H, Romdhani H, et al. Treatment patterns in men with metastatic castration sensitive prostate cancer (mCSPC) in the United States (US). J Clin Oncol. 2020;38:e19131.
18. Flaig TW, Potluri RC, Ng Y, Todd MB, Mehra M, Higano CS. Disease and treatment characteristics of men diagnosed with metastatic hormone-sensitive prostate cancer in real life: analysis from a commercial claims database. Clin Genitourin Cancer. 2017;15:273-279.e271.
19. National Cancer Institute. NCI comorbidity index overview. https://healthcaredelivery.cancer.gov/seermedicare/considerations/comorbidity.html. Accessed March 19, 2020.
20. Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med. 1997;16:385-395.
21. Thoemmes F, Ong AD. A primer on inverse probability of treatment weighting and marginal structural models. Emerging Adulthood. 2016;4:40-59.
22. Beebe-Dimmer JL, Ruterbusch JJ, Cooney KA, et al. Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: a SEER-medicare investigation. Cancer Med. 2019;8:3325-3335.
23. Schmitt B, Bennett C, Seidenfeld J, Samson D, Wilt T. Maximal androgen blockade for advanced prostate cancer. *Cochrane Database Syst Rev*. 2000;Cd001526.

24. Prostate Cancer Trialists Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. *Lancet*. 2000;355:1491-1498.

25. George DJ, Sartor O, Miller K, et al. Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States. *Clin Genitourin Cancer*. 2020;18:284-294.

26. Freedland SJ, De Hoedt AM, DerSarkissian M, et al. Veterans affairs prostate cancer treatment sequencing (VAPCaTS): a real-world evidence study of men with metastatic prostate cancer. *Urol Practice*. 2021;8:112-118.

27. RWE Navigator. Introduction to understanding and using RWE: pharmacy and health insurance databases. https://rwe-navigator.eu/use-real-world-evidence/sources-of-real-world-data/pharmacy-and-health-insurance-databases/. Accessed March 4, 2021.

28. US Dept. of Veterans Affairs. About VHA. https://www.va.gov/health/aboutva.asp. Accessed December 9, 2020.

29. Peterson K, Anderson J, Boundy E, Ferguson L, McCleery E, Waldrip K. Mortality disparities in racial/ethnic minority groups in the veterans health administration: an evidence review and map. *Am J Public Health*. 2018;108:e1-e11.

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher’s website.

**How to cite this article:** Freedland SJ, Sandin R, Sah J, et al. Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US veterans health administration. *Cancer Med*. 2021;10:8570–8580. doi:10.1002/cam4.4372